TY -的T1 - FDG PET,衰老和< em > APOE基因型< / em >在神经学认知正常的人(S8.006) JF -乔-神经学六世- 82 - 10补充SP - S8.006盟David首页 Knopman AU -克利福德杰克AU -希瑟Wiste盟-艾米丽Lundt AU -斯蒂芬Weigand盟Prashanthi Vemuri AU -杰弗里·冈特盟- Val劳盟Kejal Kantarci AU -马修Senjem盟-米歇尔Mielke盟-玫瑰花蕾罗伯茨AU -布拉德利Boeve盟罗纳德·彼得森Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/S8.006.abstract N2 -目的:检查之间的关联18 f-fluorodeoxyglucose正电子发射断层扫描(FDG PET)和年龄和评估的影响运输的APOEε4等位基因关联。背景:老化对FDG PET的影响不是很好理解,因为之前的研究使用了少量的参与者。方法:我们研究了806个认知正常(CN),和70年amyloid-imaging-positive认知受损的参与者从梅奥诊所研究衰老的,梅奥阿尔茨海默病研究中心和一个辅助研究经历了结构磁共振成像,FDG PET和11 c-pittsburgh复合B的宠物。使用部分体积修正FDG PET葡萄糖吸收比率,我们评估协会区域之氟- 18 -去氧葡萄糖摄取率随着年龄的增长和马车的APOEε4等位基因在CN参与者之间的年龄在30到95年。结果:我们发现适度的统计学意义与年龄有关的FDG比率的下降在大多数皮质和皮质下区域。我们还发现一个主要APOEε4基因型对FDG的影响比,与更大的吸收ε4非承运人与运营商相比,但只有后扣带/楔前叶,侧顶叶,AD-signature meta-ROI(后扣带/楔前叶,侧顶叶和颞下叶)。年龄和sex-matched CN参与者壁比例的差异的大小AD-signature meta-ROI为APOEε4运营商相比,非承运人小于4倍年龄的大小区别,sex-matched老年APOEε4载体CN相比,AD痴呆的参与者。结论:葡萄糖代谢会随着年龄的增长而减少。APOEε4等位基因运输与FDG比率减少后扣带/楔前叶,横向壁,降低和AD-signature roi,这些在场所有年龄。后扣带/楔前叶和侧顶叶区域有一个独特的脆弱性,降低葡萄糖代谢率函数这两个年龄和马车的APOEε4等位基因。 Study Supported by: NIH grants P50AG16574, U01AG06786, R01AG11378, Dekelboum Family Foundation, Robert & Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program.Disclosure: Dr. Knopman has received personal compensation for activities with Eli Lilly & Company and TauRx Pharmaceuticals. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Janssen and Baxter. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Co. Dr. Jack has received research support from Pfizer Inc., Allon, and Baxter. Dr. Wiste has nothing to disclose. Dr. Lundt has nothing to disclose. Dr. Weigand has nothing to disclose. Dr. Vemuri has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Lowe has received personal compensation for activities with Bayer Pharmaceuticals Corp. Dr. Lowe has received research support from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Kantarci has received research support from Pfizer Inc., Jannsen Alzheimer immunotherapy, and Takeda Global Research & Development Center. Dr. Senjem has nothing to disclose. Dr. Mielke has nothing to disclose. Dr. Roberts has received research support from Abbott Laboratories and the Driskill Foundation. Dr. Boeve has received research support from Cephalon, Inc., Allon Therapeutics, and GE Healthcare. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer's Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press.Tuesday, April 29 2014, 1:00 pm-2:45 pm ER -